Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H12N4OS |
Molecular Weight | 236.293 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1
InChI
InChIKey=SRVJKTDHMYAMHA-WUXMJOGZSA-N
InChI=1S/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+
Molecular Formula | C10H12N4OS |
Molecular Weight | 236.293 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Amithiozone, also known as thioacetazone, is an oral antibiotic, which is used in the treatment of tuberculosis. In 1991, the World Health Organization (WHO) recommended replacing thioacetazone with ethambutol in patients with known or suspected HIV infection. Thioacetazone is no longer included in WHO’s recommended first-line treatment for tuberculosis and is now reserved for uncommon situations in which treatment options have been compromised by resistance to other anti-tuberculosis medicines in HIV-negative individuals. Despite the increased recognition of this risk, thioacetazone remained in use mainly in low-income countries because of its low cost. Amithiozone has also been used in trials studying the treatment of Mycobacterium Avium-intracellular Infection. One of the possible mechanism action of the drug is interference with the metabolism of methionine of susceptible tubercle bacilli, which utilize methionine for nucleic acid synthesis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13838487 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973 Sep |
|
Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 Feb |
|
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. | 2003 Jan |
|
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. | 2005 Nov |
|
Preclinical pharmacokinetics of KBF611, a new antituberculosis agent in mice and rabbits, and comparison with thiacetazone. | 2010 Mar |
|
A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. | 2012 Nov 9 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4183287
150 mg daily doses 6 days a week over the entire treatment period for a total of
8 months.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12365582
Fifty-four strains of M. tuberculosis complex were characterised based on the minimum inhibitory concentration (MIC) of thiacetazone (amithiozone) and the growth pattern in the presence of different concentrations of the drug. The results showed that the MIC of thiacetazone to type II M. africanum strains was significantly higher than for other strains in the study (P < 0.01). Thiacetazone showed a paradoxical effect on 63% of strains where lower concentrations exhibited a better inhibiting activity than higher concentrations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:22:56 GMT 2023
by
admin
on
Fri Dec 15 17:22:56 GMT 2023
|
Record UNII |
MMG78X7SSR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C280
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
||
|
WHO-ATC |
J04AK07
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
||
|
WHO-VATC |
QJ04AM04
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
||
|
WHO-ATC |
J04AM04
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10975MIG
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
252
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
203-170-6
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
9568512
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
104-06-3
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
THIOACETAZONE
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
D013828
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
MMG78X7SSR
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
C90769
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
m10712
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL375492
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
3550
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
100000082400
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
2631
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
DTXSID2022593
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
DB12829
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | |||
|
AMITHIOZONE
Created by
admin on Fri Dec 15 17:22:56 GMT 2023 , Edited by admin on Fri Dec 15 17:22:56 GMT 2023
|
PRIMARY | Description: Pale yellow crystals or a yellow, crystalline powder; almost odourless. Solubility: Very slightly soluble in water; slightly soluble in ethanol (~750 g/l) TS and methanol R; soluble in 10 parts of dimethylformamide R. Category: Antituberculosis drug. Storage: Thioacetazone should be kept in a tightly closed container, protected from light. Definition: Thioacetazone contains not less than 98.0% and not more than 102.0% of C10H12N4OS, calculated with reference to the dried substance. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |